Prospective, Multicentre, Open-label, Single-arm, Non-interventional Regulatory Post-marketing Surveillance(rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda (Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea
Latest Information Update: 13 Jul 2021
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 15 Jan 2021 Status changed from active, no longer recruiting to completed.
- 09 Nov 2020 Planned primary completion date changed from 20 Oct 2020 to 20 Nov 2020.
- 28 Oct 2020 Planned End Date changed from 20 Oct 2020 to 20 Nov 2020.